Patents by Inventor Josh Ketterman

Josh Ketterman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
    Patent number: 9265764
    Abstract: Aspects of this invention are related, at least in part, to the use of chemical compounds able to inhibit GSK-3 and/or to stabilize ?-catenin and formulations thereof. Some aspects of this invention relate to compositions comprising such compounds. Some aspects of the invention provide methods of using such compounds and/or compositions in the treatment of subjects having a neurological disease and/or psychiatric disorder. Some aspects of this invention provide methods of using ruboxistaurin, enzastaurin, sunitinib, midostaurin, lestaurtinib, 7-hydroxystaurosporine, and/or Chir99021 in the treatment of subjects having a neurological disease and/or psychiatric disorder. In some embodiments, compounds are administered in combination with Lithium.
    Type: Grant
    Filed: February 27, 2010
    Date of Patent: February 23, 2016
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation
    Inventors: Stephen J. Haggarty, Daniel Fass, Jennifer Pan, Josh Ketterman, Edward Holson, Tracey Lynn Petryshen, Michael C. Lewis
  • Uses of chemicals to modulate GSK-3 signaling for treatment of bipolar disorder and other brain disorders
    Publication number: 20110008468
    Abstract: Aspects of this invention are related, at least in part, to the use of chemical compounds able to inhibit GSK-3 and/or to stabilize ?-catenin and formulations thereof. Some aspects of this invention relate to compositions comprising such compounds. Some aspects of the invention provide methods of using such compounds and/or compositions in the treatment of subjects having a neurological disease and/or psychiatric disorder. Some aspects of this invention provide methods of using ruboxistaurin, enzastaurin, sunitinib, midostaurin, lestaurtinib, 7-hydroxystaurosporine, and/or Chir99021 in the treatment of subjects having a neurological disease and/or psychiatric disorder. In some embodiments, compounds are administered in combination with Lithium.
    Type: Application
    Filed: February 27, 2010
    Publication date: January 13, 2011
    Inventors: Stephen J. Haggarty, Daniel Fass, Jennifer Pan, Josh Ketterman, Edward Holson, Tracey Lynn Petryshen, Michael C. Lewis